• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Evoke Acquires Navience Healthcare Solutions, LLC

Share:

October 1, 2018

Adds Depth and Breadth in High-Growth Market Access & Payer Marketing Sector

Evoke, part of Huntsworth plc, today announces the acquisition of New Jersey-based Navience Healthcare Solutions. Navience is a full-service market access and payer marketing agency helping clients navigate the complexities of the ever-changing market access landscape by identifying, developing and executing tailored solutions, backed by a robust analytics offering. The acquisition is expected to complete in early October.

“The influence of the payer, in the medical decision-making process and to the success or failure of any given product in today’s healthcare landscape, cannot be overstated,” said Reid Connolly, CEO of Evoke. “This influence affects the strategies and solutions we offer clients across all audiences and channels. That’s why Navience is such an ideal fit within our agency, adding incredible value to the marketing and communications expertise our client partners require.”

Led by Principal John Shamsey, a client-side veteran, Navience has quickly grown to become one of the leaders in the Market Access and Payer marketing space. The Navience team delivers a customer-centric approach offering clients a full spectrum of services from research and insights, advanced analytics to a full suite of creative and agency services. Shamsey will continue to lead Navience, serving on the Evoke leadership team and reporting to Reid Connolly. As an integral part of the Evoke team, the agency will now be called Evoke Navience.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Reid and his team have built one of the more impressive and progressive agency brands and one with such a diverse offering,” said John Shamsey. “They’ve truly established themselves as one of the few agencies of scale that clients can turn to for their toughest challenges, regardless of audience, channel, or geography and we’re looking forward to working together to help solve those problems together.”

“As the healthcare market becomes more fragmented and our clients’ resources become more stretched, our ability to be the one partner who can help navigate them through it is even more critical now than ever,” said Connolly. “We couldn’t be happier to have John and his team become part of the Evoke team.”

Date: October 1, 2018

Source: Cision

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Global pharma solutions partner Envision Pharma will add OKRA.ai to its platform this month, building on its suite of pharma applications.Global pharma solutions partner Envision Pharma will add OKRA.ai to its platform this month, building on its suite of pharma applications.
  • Addiction Focused Startup Quit Genius Scores $11M in Series A FundingAddiction Focused Startup Quit Genius Scores $11M in Series A Funding
  • EverlyWell Raises $50M to Scale In-Home Digital Lab Testing PlatformEverlyWell Raises $50M to Scale In-Home Digital Lab Testing Platform
  • UT Southwestern Medical Center Researchers Discover Alzheimer’s Vaccine, Hope To Test In Humans SoonUT Southwestern Medical Center Researchers Discover Alzheimer’s Vaccine, Hope To Test In Humans Soon
  • Water Street Completes Dual Acquisitions to Continue Building Life Sciences Commercialization Services PlatformWater Street Completes Dual Acquisitions to Continue Building Life Sciences Commercialization Services Platform
  • Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead SciencesSierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
  • Cryoport Acquires Temperature-Controlled Logistics Provider in AustraliaCryoport Acquires Temperature-Controlled Logistics Provider in Australia
  • Lab Notebook learns to communicate with laboratory devices: labfolder acquires cubuslab and becomes LabforwardLab Notebook learns to communicate with laboratory devices: labfolder acquires cubuslab and becomes Labforward

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications